Title : Emerging mycoses in the 21st century: Epidemiology, global burden, and the urgent imperative for vaccine development
Abstract:
Fungal infections/diseases of humans, called mycoses, affect 1–2 billion people each year worldwide, spanning mild superficial skin infections (ringworm, onychomycosis) to fatal invasive systemic mycoses. The causative agents (yeasts and molds) have developed resistance against antifungal drugs, and these superbugs are emerging at a fast pace, representing a rapidly escalating global health threat in the 21st century. Historically overlooked, these infections are classified into superficial, subcutaneous, opportunistic, and endemic systemic mycoses. Criteria used to diagnose these infections have transitioned from traditional, slow microscopic evaluation and histopathology to advanced non-culture-based tools, including serological antigen assays, novel PCR assays, and next-generation sequencing. Modern epidemiological data reveals a stark rise in global incidence—accounting for over 6.5 million life-threatening invasive cases and 3.8 million deaths annually. This surge is driven by an expanding population of highly vulnerable hosts, including individuals with HIV/AIDS, cancer patients, and transplant recipients. In the United States alone, the annual economic toll of fungal diseases is estimated at a staggering $19.4 billion USD, including $13.4 billion USD in direct medical costs alongside productivity losses.
A critical milestone in addressing this threat was the 2022 release of the World Health Organization (WHO) Fungal Priority Pathogens List (WHO, 2022). Among the most dangerous globally are invasive candidiasis, cryptococcosis, coccidioidomycosis, and invasive aspergillosis, the latter of which stands out as arguably the most lethal with a crude mortality rate of up to 90% in immunocompromised hosts. Concurrently, the "superbug" Candida auris has emerged as a perilous, multidrug-resistant healthcare-associated pathogen, spreading rapidly through US hospitals and long-term care facilities. The US Centers for Disease Control and Prevention (CDC) classifies C. auris as an urgent antimicrobial resistance threat due to its ability to persist tenaciously on medical surfaces, cause severe bloodstream infections, and resist multiple major antifungal classes. The wider surge in these mycoses is propelled by multifactorial drivers, including climate change (selecting for thermal tolerance), global travel, environmental disruption, and widespread agricultural fungicide use.
Current management relies on a severely limited armamentarium of only four primary antifungal classes (polyenes, azoles, echinocandins, and pyrimidine analogs), many of which suffer from high toxicity and severe drug interactions. This treatment crisis underscores the critical need for preventative interventions. Currently, no licensed fungal vaccines exist for human use, though candidates like NDV-3A and PEV7 are navigating clinical trials. Developing effective vaccines for fatal fungal infections is a critical necessity to shift the paradigm from reactive, failure-prone treatment to proactive prevention. Vaccines offer the most viable shield to protect highly vulnerable populations, curb the rise of antimicrobial resistance by reducing selective pressure, and ultimately mitigate the high global mortality and economic devastation wrought by modern mycoses.
Keywords: Emerging mycoses, Antifungal resistance, Candida auris, WHO priority pathogens, Fungal vaccines

